Orphazyme Revenue and Competitors

Claim your profile

Denmark

Location

$263.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Orphazyme's estimated annual revenue is currently $13.2M per year.(i)
  • Orphazyme's estimated revenue per employee is $337,179
  • Orphazyme's total funding is $263.3M.
  • Orphazyme's current valuation is $79.8M. (January 2022)

Employee Data

  • Orphazyme has 39 Employees.(i)
  • Orphazyme grew their employee count by -83% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7910M193245%$204.3MN/A
#2
$31.9M20623%N/AN/A
#3
$3.4M88123%$85.7MN/A
#4
$13.2M39-83%$263.3MN/A
#5
$16.1M10416%N/AN/A
#6
$2.6M1755%N/AN/A
#7
$8.7M56409%N/AN/A

Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases, including sporadic Inclusion Body Myositis (sIBM), Amyotrophic Lateral Sclerosis (ALS), Niemann Pick Type C (NPC), and Gaucher. Anticipated completion of three potential registration studies by end 2020, with the first potential marketing authorization in 2020.

keywords:N/A

$263.3M

Total Funding

39

Number of Employees

$13.2M

Revenue (est)

-83%

Employee Growth %

$79.8M

Valuation

N/A

Accelerator

Orphazyme News

2022-03-30 - Correction: Proposal for a statutory restructuring plan

Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Orphazyme is headquartered in...

2022-03-30 - Proposal for a statutory restructuring plan

Copenhagen, Denmark, March 31, 2022 – Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage...

2022-03-30 - Updated Financial Calendar for 2022

Copenhagen, Denmark, March 29, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage...

2019-08-28 - Orphazyme Partnership to Run Through Extension of Phase 3 ...

Orphazyme announced that it and Worldwide Clinical Trials will continue their collaboration through the long-term extension of a Phase 3 study ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.1M39-22%N/A
#2
$8.4M39-17%N/A
#3
$7.7M390%N/A
#4
$7.3M3939%N/A
#5
$3.7M39-32%N/A